On Nov. 20, the Food and Drug Administration (FDA) of the Ministry of Health and Welfare ordered the recall of all 80mg and 160mg Prevan film-coated tablets — medication for high blood pressure produced by Genovate Biotechnology Co (健亞生物科技) — after the drug was found to contain a carcinogenic chemical.
As there have been three recalls of blood pressure medication in only a few months, questions need to be asked about what is wrong with the quality control of imported pharmaceutical ingredients, and what else the FDA should do in addition to ordering recalls?
In the past, finding raw material supply sources and quality control were mostly the responsibility of pharmaceutical companies, which self-managed in accordance with the Good Manufacturing Practice (GMP) standard.
Although GMP is in common use internationally, raw material safety issues occur often. As a result, all countries have been re-evaluating and improving source review and inspection management to ensure the safety of medication.
There are some feasible actions that the FDA could take. In terms of post-approval inspection, it could integrate written and on-the-spot inspections to implement risk management at pharmaceutical companies and factories, and ensure that the medication production information is identical to the registered information.
For high-risk items, it could plan for inspectors to verify whether the product documents are in line with the documents issued following the original inspection.
Also, during factory inspections, the FDA could conduct random sample testing and improve the inspection of supplier approval and supervision in accordance with the Pharmaceutical Inspection Cooperation Scheme (PIC/S) and GMP to maintain product quality and safety.
In addition to regular factory inspections, extra factory checks could be conducted in response to special incidents, such as when a company is being reported, a marketed product fails a quality test, a defective product is reported or if there has been a related news report.
To ensure the quality of products on the market, the FDA could conduct theme-based inspections and send inspectors to collect samples directly from factories, so as to monitor quality. If a product fails a test, the FDA should order the company to recall the drug.
Despite the FDA’s recall demand, it is reported that local health bureaus nationwide do not have sufficient personnel to conduct inspections.
Perhaps the FDA could demand that local hospitals, clinics and pharmacies remove the products from their shelves by promptly passing the information to them through its penalty mechanism. Patients who are taking the defective drug could ask doctors to replace it with similar high blood pressure medication.
Despite the series of high blood pressure drug recalls in recent months, it seems as if the FDA is merely being reactionary, fixing holes after they are discovered.
What could it do to tighten the quality control of imported pharmaceutical ingredients? Should it not look into where the responsibility lies if strict inspections are not carried out on raw material imports?
A government that only demands recalls, but does not review the handling of a case, look into accountability or demand compensation from the medical companies involved, can hardly be said to be responsible.
Liu Dian-ke is a pharmacist and a doctoral student of business administration at National Chung Cheng University.
Translated by Eddy Chang
Two sets of economic data released last week by the Directorate-General of Budget, Accounting and Statistics (DGBAS) have drawn mixed reactions from the public: One on the nation’s economic performance in the first quarter of the year and the other on Taiwan’s household wealth distribution in 2021. GDP growth for the first quarter was faster than expected, at 6.51 percent year-on-year, an acceleration from the previous quarter’s 4.93 percent and higher than the agency’s February estimate of 5.92 percent. It was also the highest growth since the second quarter of 2021, when the economy expanded 8.07 percent, DGBAS data showed. The growth
In the intricate ballet of geopolitics, names signify more than mere identification: They embody history, culture and sovereignty. The recent decision by China to refer to Arunachal Pradesh as “Tsang Nan” or South Tibet, and to rename Tibet as “Xizang,” is a strategic move that extends beyond cartography into the realm of diplomatic signaling. This op-ed explores the implications of these actions and India’s potential response. Names are potent symbols in international relations, encapsulating the essence of a nation’s stance on territorial disputes. China’s choice to rename regions within Indian territory is not merely a linguistic exercise, but a symbolic assertion
More than seven months into the armed conflict in Gaza, the International Court of Justice ordered Israel to take “immediate and effective measures” to protect Palestinians in Gaza from the risk of genocide following a case brought by South Africa regarding Israel’s breaches of the 1948 Genocide Convention. The international community, including Amnesty International, called for an immediate ceasefire by all parties to prevent further loss of civilian lives and to ensure access to life-saving aid. Several protests have been organized around the world, including at the University of California Los Angeles (UCLA) and many other universities in the US.
Every day since Oct. 7 last year, the world has watched an unprecedented wave of violence rain down on Israel and the occupied Palestinian Territories — more than 200 days of constant suffering and death in Gaza with just a seven-day pause. Many of us in the American expatriate community in Taiwan have been watching this tragedy unfold in horror. We know we are implicated with every US-made “dumb” bomb dropped on a civilian target and by the diplomatic cover our government gives to the Israeli government, which has only gotten more extreme with such impunity. Meantime, multicultural coalitions of US